NEW YORK, NY / ACCESSWIRE / December 23, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Raytheon Technologies Corporation (NYSE:RTX)

Investors Affected : February 10, 2016 - October 27, 2020

A class action has commenced on behalf of certain shareholders in Raytheon Technologies Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and inadequate internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon Company's Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/raytheon-technologies-corporation-loss-submission-form/?id=11780&from=1

Zosano Pharma Corporation (NASDAQ:ZSAN)

Investors Affected : February 13, 2017 - September 30, 2020

A class action has commenced on behalf of certain shareholders in Zosano Pharma Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.